Q32 Bio QTTB 深 沪
等待开盘 10-09 09:30:00 美东时间
8.09
+0.100
+1.25%
华盛通- 最 高8.12
- 今 开7.94
- 成交量 86.02万股
- 最 低 7.62
- 昨 收 7.99
- 总市值 2.41亿
- 52周最高 23.5699
- 市盈率 静 3.34
- 换手率 2.89%
- 52周最低 1.905
- 委 比 -25.00%
- 总股本 2976.95万
- 历史最高 572.40
- 量 比 0.58
- 振 幅 6.26%
- 历史最低 1.345
- 每 手 1
- 风险率 4.71%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 潜在涨幅919.61%！HC Wainwright上调NeuroSense Therapeutics目标价至52美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持NeuroSense Therapeutics"买入"评级，目标价从8美元升至52美元；HC Wainwright & Co.：维持艾切托"买入"评级，目标价从27美元升至34美元
09-29 08:33
Jefferies Initiates Coverage On Q32 Bio with Buy Rating, Announces Price Target of $29
Jefferies analyst Maury Raycroft initiates coverage on Q32 Bio (NASDAQ:QTTB) with a Buy rating and announces Price Target of $29.
09-28 22:01
Gene editing stocks fall after Anthropic’s CRISPR-like discovery
Gene editing companies traded lower on Wednesday after Anthropic (ANTHRO) said that its AI model Claude has “autonomously discovered” a new enzyme system similar to the gene-editing tool CRISPR. Notab...
09-24 02:33
Small-cap stocks with strong momentum grades and triple-digit YTD gains
A group of U.S. small-cap stocks is flashing A+ momentum grades in the latest quantitative screen, with several names posting triple-digit gains year to date. Seeking Alpha's Quant Momentum Grade meas...
09-17 21:55
Q32 Bio Appoints José Trevejo, M.D., Ph.D., as Chief Medical Officer and Ellie Hershberger, Pharm.D., as Chief Development Officer
-- Dr. Trevejo is a physician-scientist and biotechnology executive with over 20 years of experience spanning dermatology and late-stage clinical development -- -- Dr. Hershberger is a drug ...
09-14 18:59
Akebia Therapeutics Announces First Patient Dosed in Phase 2 Basket Trial of Ebribafusp in Rare Complement-Mediated Kidney Diseases
Akebia Therapeutics启动II期临床试验，评估ebribafusp治疗IgA肾病、狼疮性肾炎和C3肾小球病的效果。ebribafusp是一种 investigational 的下一代抗C3d因子H融合蛋白，旨在抑制组织中的补体激活，而不影响血液中的补体系统。试验计划招募最多30名患者，每周一次皮下注射，持续26周，随后是长期扩展研究。主要终点是不良事件的发生率，次要终点包括蛋白尿变化、肾功能和药代动力学。Akebia Therapeutics专注于改善肾脏疾病患者的生活，并在2025年从Q32 Bio获得了ebribafusp的全球权利。初步数据预计在2027年公布。
09-14 12:00
Quant Check: Top- and bottom-rated small-cap healthcare stocks post-earnings
As earnings season ends, investors are turning to updated Quant ratings to see how companies stack up after their latest results. These ratings grade stocks on key metrics like value, growth, profits,...
09-01 22:25
美股大行评级 | 首予买入！Jersey Mike's获13家大行评级；大摩、富国银行齐上调迈威尔科技目标价，最高升至310美元
今日重点评级关注：Truist Securities：维持CoreWeave"买入"评级，目标价从155美元升至165美元；百德：维持亚德诺"跑赢大市"评级，目标价从450美元升至675美元
08-25 11:47
Morgan Stanley Initiates Coverage On Q32 Bio with Overweight Rating, Announces Price Target of $34
Morgan Stanley analyst Judah Frommer initiates coverage on Q32 Bio (NASDAQ:QTTB) with a Overweight rating and announces Price Target of $34.
08-24 18:17
Q32 Bio Q2 EPS $(0.44) Beats $(0.54) Estimate
Q32 Bio (NASDAQ:QTTB) reported quarterly losses of $(0.44) per share which beat the analyst consensus estimate of $(0.54) by 18.52 percent. This is a 43.59 percent increase over losses of $(0.78) per share from the same period last year.
08-05 19:21
